Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals’ chief legal officer, Shawnte Mitchell, received new stock-based awards. On February 2, 2026, Mitchell was granted stock options to buy 220,000 shares of common stock at an exercise price of $25.65 per share, expiring February 1, 2036.
These time-based options vest 25% on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. Mitchell was also granted 56,250 performance-based stock options at the same $25.65 exercise price, also expiring February 1, 2036.
The performance options may vest in two performance periods beginning February 2, 2026 and ending December 31, 2029 and December 31, 2030, if Olema’s stock achieves specified average price thresholds over a 30-day trading period and the compensation committee certifies achievement, subject to Mitchell’s continued service.
Olema Pharmaceuticals reported new equity awards to President and CEO Sean Bohen. On February 2, 2026, he received a stock option to buy 850,000 shares at an exercise price of $25.65. These options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years, subject to continued service.
On the same date, Bohen also received 275,000 performance-based stock options at an exercise price of $25.65. These can vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, if Olema’s share price meets specified thresholds over a 30-day trading average and the compensation committee certifies achievement. If his service is terminated without cause, these performance options remain eligible to vest for 12 months.
Olema Pharmaceuticals announced that Chief Operating and Financial Officer Shane Kovacs is leaving the company effective January 30, 2026, to pursue new opportunities. He will remain as a consultant through August 1, 2026, and his existing equity awards will continue to vest during this period.
Under a separation and consulting agreement, Kovacs will receive a lump-sum payment of $621,283, including $562,640 (12 months of base salary), $23,443 (pro-rated 2026 target bonus at 100% achievement), and $35,200 for COBRA health coverage gross-up. The company states his departure is not due to any disagreement over financial operations, policies, or practices. CEO Sean Bohen, M.D., Ph.D., has taken on the role of interim principal financial officer until a new Chief Financial Officer is appointed.
Olema Pharmaceuticals director Cyrus Harmon reported a sale of company stock. On January 20, 2026, he sold 10,000 shares of Olema Pharmaceuticals common stock at a weighted average price of $26.88 per share, with individual trade prices ranging from $26.85 to $26.96. Following this transaction, he directly held 727,770 common shares.
The filing also notes an additional 117,028 common shares held indirectly through Harmon Family Investors LLC, where Harmon serves as manager, reflecting his indirect beneficial ownership interest alongside his direct holdings.
Cyrus L. Harmon has filed a notice of proposed sale of 10,000 shares of OLMA common stock under Rule 144. The shares are planned to be sold through Fidelity Brokerage Services LLC on or around 01/20/2026 on the NASDAQ, with an indicated aggregate market value of 268,762.74. The filing notes that 68,659,923 shares of OLMA common stock are outstanding.
The 10,000 shares were originally acquired on 03/20/2007 as founder shares, recorded as compensation. Over the prior three months, Harmon sold 2,881 OLMA common shares on 12/22/2025 for gross proceeds of 82,182.00 and 3,489 shares on 01/14/2026 for gross proceeds of 101,603.33. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Olema Pharmaceuticals director Harmon Cyrus reported an open-market sale of common stock. On January 14, 2026, he sold 3,489 shares of Olema Pharmaceuticals, Inc. common stock at a weighted average price of $29.12 per share, with individual trade prices ranging from $29.00 to $29.23.
After this transaction, Cyrus beneficially owns 737,770 shares directly. He also reports 117,028 additional shares held indirectly through the Harmon Family Investors LLC, of which he is the manager.
Olema Pharmaceuticals, Inc. chief operating and financial officer Shane William Charles Kovacs reported selling company common stock in two open-market transactions. On January 13, 2026, he sold 3,822 shares at a weighted average price of $28.01, within a price range of $28.00 to $28.03. On January 15, 2026, he sold 100,000 shares at a weighted average price of $28.73, within a price range of $28.50 to $29.18.
Following these transactions, Kovacs directly owned 139,727 shares of Olema Pharmaceuticals common stock.
Shane W. Kovacs filed a notice of proposed sale of securities on Form 144 covering up to 100,000 shares of common stock. The shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/15/2026 and an indicated aggregate market value of $2,873,214.99. The filing notes that 68,659,923 common shares were outstanding.
The shares to be sold were acquired between 2020 and 2024 through restricted stock vesting, open market purchases, and employee stock purchase plan (ESPP) purchases from the issuer. The notice also reports that during the past three months, Kovacs sold 3,822 common shares on 01/13/2026 for $107,069.20 in gross proceeds.
Olema Pharmaceuticals executive David C. Myles reported multiple stock option exercises and share sales. On January 13 and 14, he exercised a total of 100,000 stock options at an exercise price of $4.87 per share, resulting in 50,000 stock options remaining outstanding. Over January 13–14, he sold 100,000 shares of common stock in the market at weighted average prices ranging from $27.60 to $28.99 per share, leaving 542,761 shares held directly.
An entity associated with him, Myles Properties Inc., sold 10,000 shares on January 12 at a weighted average price of $28.34, and continued to hold 144,846 shares indirectly. A family trust associated with him held an additional 12,831 shares indirectly. The filing also notes that a prior Form 4 overstated his directly owned shares by 120 shares due to a scrivener's error, which is corrected here.
Cyrus L. Harmon has filed a notice of proposed sale of 3,489 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services LLC on or about 01/14/2026 on the NASDAQ market. Based on the figures provided, the aggregate market value of the planned sale is $101,603.33, and the issuer has 68,659,923 shares of common stock outstanding.
The shares to be sold were originally acquired as founder shares on 03/20/2007 as compensation from the issuer. Over the past three months, Harmon has already sold 2,881 common shares on 12/22/2025 for gross proceeds of $82,182.00. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.